GI Innovation, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.gi-innovation.com
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05824975
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Minnesota, Rochester, Minnesota, United States
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT04977453
- Locations
- 🇺🇸
Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York, United States
🇺🇸Carolina Biooncology Institute, Huntersville, North Carolina, United States
🇰🇷The Catholic University of Korea St. Vincent's Hospital, Suwon-si, Kyeonggi-do, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath